Skip to main content
SpringerLink
Log in

Implementation of CT-P13 via a Managed Switch Programme in Crohn’s Disease: 12-Month Real-World Outcomes

  • Original Article
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Background

Switching from Remicade to CT-P13 allows for significant cost savings and has been shown to be non-inferior to continued therapy with Remicade for the treatment of Crohn’s disease.

Aim

The aim of this work was to prospectively evaluate clinical outcomes in a cohort of patients with Crohn’s disease switching from Remicade to CT-P13.

Methods

A prospective service evaluation was performed. The Harvey-Bradshaw index, CRP, faecal calprotectin and serum for infliximab/antibody levels were collected prior to patients' final Remicade infusion and at 6 and 12 months after switching to CT-P13 as part of routine clinical care. All adverse events during follow-up were also recorded.

Results

One hundred and ten patients on Remicade switched to CT-P13. No significant difference was observed between the Harvey-Bradshaw Index (p = 0.07), CRP (p = 0.13), faecal calprotectin (p = 0.25) or trough infliximab levels (p = 0.47) comparing before and at 6 and 12 months after the switch to CT-P13. Seven patients developed new infliximab antibodies after switching from Remicade to CT-P13. The majority of patients remained on CT-P13 at 12 months (84.5%) and the rate of adverse events and serious adverse events was 53.8 and 13.5 per 100 patient-years of follow-up, respectively. Switching to CT-P13 resulted in a cost saving of approximately 46.4%.

Conclusion

The transition to CT-P13 from Remicade for the treatment of Crohn’s disease is safe and has no negative effect on clinical outcomes at 12 months.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359:1541–1549. https://doi.org/10.1016/S0140-6736(02)08512-4.

    Article  CAS  PubMed  Google Scholar 

  2. D’Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet. 2008;371:660–667. https://doi.org/10.1016/S0140-6736(08)60304-9.

    Article  CAS  PubMed  Google Scholar 

  3. Colombel JJF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease (SONIC study). N Engl J Med. 2010;362:1383–1395. https://doi.org/10.1056/NEJMoa0904492.

    Article  CAS  PubMed  Google Scholar 

  4. Khanna R, Bressler B, Levesque BG, et al. Early combined immunosuppression for the management of Crohn’s disease (REACT): a cluster randomised controlled trial. Lancet. 2015;386:1825–1834. https://doi.org/10.1016/S0140-6736(15)00068-9.

    Article  PubMed  Google Scholar 

  5. Van Der Valk ME, Mangen MJJ, Leenders M, et al. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study. Gut. 2014;63:72–79. https://doi.org/10.1136/gutjnl-2012-303376.

    Article  PubMed  Google Scholar 

  6. European Medicines Agency, Committee for Medicinal Products for Human Use. Assessment Report 2013. http://www.ema.europa.eu.ezproxy.is.ed.ac.uk/docs/en_GB/document_library/EPAR_Public_assessment_report/human/002778/WC500151490.pdf.

  7. Kim YH, Ye BD, Pesegova M, et al. Phase III randomised, double-blind, controlled trial to compare biosimilar infliximab (CT-P13) with innovator infliximab (INX) in patients with active Crohn’s disease: early efficacy and safety results. DOP061, presented at ECCO 2017.

  8. Jahnsen J, Detlie TE, Vatn S, Ricanek P. Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: a Norwegian observational study. Expert Rev Gastroenterol Hepatol. 2015;9:S45–S52. https://doi.org/10.1586/17474124.2015.1091308.

    Article  Google Scholar 

  9. Gecse KB, Lovász BD, Farkas K, et al. Efficacy and safety of the biosimilar infliximab CT-P13 treatment in inflammatory bowel diseases: a prospective, multicentre, nationwide cohort. J Crohn’s Colitis. 2016;10:133–140. https://doi.org/10.1093/ecco-jcc/jjv220.

    Article  Google Scholar 

  10. Argüelles-Arias F, Guerra Veloz MF, Perea Amarillo R, et al. Effectiveness and safety of CT-P13 (biosimilar infliximab) in patients with inflammatory bowel disease in real life at 6 months. Dig Dis Sci. 2017;62:1305–1312. https://doi.org/10.1007/s10620-017-4511-4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Fiorino G, Manetti N, Armuzzi A, et al. The PROSIT-BIO cohort. Inflamm Bowel Dis. 2017;23:233–243. https://doi.org/10.1097/MIB.0000000000000995.

    Article  PubMed  Google Scholar 

  12. Jørgensen KK, Olsen IC, Goll GL, et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet. 2017;389:2304–2316. https://doi.org/10.1016/S0140-6736(17)30068-5.

    Article  PubMed  Google Scholar 

  13. Joergensen KK, Olsen IC, Goll GL, et al. Biosimilar infliximab (CT-P13) is not inferior to originator infliximab: explorative IBD subgroup-analyses in Crohn’s disease and ulcerative colitis from the Nor-Switch trial. Gastroenterology. 2017;152:S65–S66. https://doi.org/10.1016/S0016-5085(17)30572-3.

    Article  Google Scholar 

  14. Kim YH, Ye BD, Pesegova H, et al. Phase III randomized controlled trial to compare biosimilar infliximab (CT-P13) with innovator infliximab in patients with active Crohn’s disease: 1-year maintenance and switching results. Abstract LB04. Presented at UEGW 2017.

  15. Razanskaite V, Bettey M, Downey L, et al. Biosimilar infliximab in inflammatory bowel disease: outcomes of a managed switching programme. J Crohn’s Colitis. 2017;11:690–696. https://doi.org/10.1093/ecco-jcc/jjw216.

    Article  Google Scholar 

  16. Sipponen T, Savilahti E, Karkkainen P, et al. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn’s disease. Inflamm Bowel Dis. 2008;14:1392–1398. https://doi.org/10.1002/ibd.20490.

    Article  PubMed  Google Scholar 

  17. Arguëlles-Arias F, Guerra Veloz MF, Perea Amarillo R, et al. Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: 12 months results. Eur J Gastroenterol Hepatol. 2017;29:1290–1295. https://doi.org/10.1097/MEG.0000000000000953.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Smits LJT, Grelack A, Derikx LAAP, et al. Long-term clinical outcomes after switching from Remicade® to biosimilar CT-P13 in inflammatory bowel disease. Dig Dis Sci. 2017;62:3117–3122. https://doi.org/10.1007/s10620-017-4661-4.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Eberl A, Huoponen S, Pahikkala T, Blom M, Arkkila P, Sipponen T. Switching maintenance infliximab therapy to biosimilar infliximab in inflammatory bowel disease patients. Scand J Gastroenterol. 2017;52:1348–1353. https://doi.org/10.1080/00365521.2017.1369561.

    Article  CAS  PubMed  Google Scholar 

  20. Buer LCT, Moum BA, Cvancarova M, Warren DJ, Medhus AW, Høivik ML. Switching from Remicade® to Remsima® is well tolerated and feasible: a prospective, open-label study. J Crohn’s Colitis. 2017;11:297–304. https://doi.org/10.1093/ecco-jcc/jjw166.

    Article  Google Scholar 

  21. Binkhorst L, Sobels A, Stuyt R, Westerman EM, West RL. Switching to a infliximab biosimilar: short-term results of clinical monitoring in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2018;30:699–703. https://doi.org/10.1097/meg.0000000000001113.

    Article  CAS  PubMed  Google Scholar 

  22. Schmitz EMH, Boekema PJ, Straathof JWA, et al. Switching from infliximab innovator to biosimilar in patients with inflammatory bowel disease: a 12-month multicentre observational prospective cohort study. Aliment Pharmacol Ther. 2018;47:356–363. https://doi.org/10.1111/apt.14453.

    Article  CAS  PubMed  Google Scholar 

  23. Ratnakumaran R, To N, Gracie DJ, et al. Efficacy and tolerability of initiating, or switching to, infliximab biosimilar CT-P13 in inflammatory bowel disease (IBD): a large single-centre experience. Scand J Gastroenterol. 2018;53:700–707. https://doi.org/10.1080/00365521.2018.1464203.

    Article  CAS  PubMed  Google Scholar 

  24. Høivik ML, Buer LCT, Cvancarova M, et al. Switching from originator to biosimilar infliximab—real world data of a prospective 18 months follow-up of a single-centre IBD population. Scand J Gastroenterol. 2018;53:692–699. https://doi.org/10.1080/00365521.2018.1463391.

    Article  CAS  PubMed  Google Scholar 

  25. Bortlik M, Duricova D, Malickova K, et al. Infliximab trough levels may predict sustained response to infliximab in patients with Crohn’s disease. J Crohn’s Colitis. 2013;7:736–743. https://doi.org/10.1016/j.crohns.2012.10.019.

    Article  Google Scholar 

  26. Casteele NV, Khanna R, Levesque BG, et al. The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn’s disease. Gut. 2015;64(10):1539–1545. https://doi.org/10.1136/gutjnl-2014-307883.

    Article  CAS  Google Scholar 

Download references

Acknowledgments

We acknowledge all the staff at the day unit infusion suite, Ward 75, Western General Hospital, Edinburgh, for their help and assistance with this work.

Author information

Authors and Affiliations

  1. The Edinburgh IBD Unit, Western General Hospital, Edinburgh, EH4 2XU, UK

    Nikolas Plevris, Gareth R. Jones, Philip W. Jenkinson, Mathew Lyons, Cher S. Chuah, Lynne M. Merchant, Eleanor F. Watson, Gwo-Tzer Ho, Colin L. Noble, Shahida Din, Alan G. Shand, Ian D. Arnott & Charlie W. Lees

  2. Department of Clinical Biochemistry, Western General Hospital, Edinburgh, EH4 2XU, UK

    Rebecca J. Pattenden

Authors
  1. Nikolas Plevris
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gareth R. Jones
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Philip W. Jenkinson
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mathew Lyons
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Cher S. Chuah
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Lynne M. Merchant
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Rebecca J. Pattenden
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Eleanor F. Watson
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Gwo-Tzer Ho
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Colin L. Noble
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Shahida Din
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Alan G. Shand
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Ian D. Arnott
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Charlie W. Lees
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

NP designed the study, collected and analysed the data, wrote the manuscript. GRJ collected and analysed the data, critically revised the manuscript. PWJ collected the data and critically revised the manuscript. ML analysed the data and critically revised the manuscript. CSC, LMM, RJP collected the data and critically revised the manuscript. EFW, GH, CLN, SD, AGS, IDA designed the study and critically revised the manuscript. CWL designed the study, analysed the data and critically revised the manuscript. All authors approved the final version of the manuscript.

Corresponding author

Correspondence to Nikolas Plevris.

Ethics declarations

Conflict of interest

NP has received consultancy fees from Takeda and speaker fees and travel support from AbbVie, Takeda and Norgine. EFW has received travel support from AbbVie. SD has received travel support from AbbVie and Dr. Falk. CLN has received consultancy fees from Vifor. AGS has received travel support from AbbVie. IDA has received consultancy fees from Vifor and travel support from Shire. CWL has received research support from AbbVie and Shire, consultancy fees from AbbVie, Pfizer, Dr. Falk, Hospira, MSD, Pharmacosmos, Takeda and Vifor, and speaker fees and travel support from AbbVie, Pfizer, Dr. Falk, Ferring, Hospira, MSD, Shire, Takeda and Warner-Chilcott. GRJ, PWJ, ML, CSC, LMM, RJP, and GTH have no personal interests to declare.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Plevris, N., Jones, G.R., Jenkinson, P.W. et al. Implementation of CT-P13 via a Managed Switch Programme in Crohn’s Disease: 12-Month Real-World Outcomes. Dig Dis Sci 64, 1660–1667 (2019). https://doi.org/10.1007/s10620-018-5406-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-018-5406-8

Keywords

Search

Navigation